

Ruxolitinib 5mg, 10mg, 15mg and 20mg tablets (Jakavi®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2498	For the treatment of: *patients aged 12 years and older with acute graft versus host disease who have inadequate response to corticosteroids. *patients aged 12 years and older with chronic graft versus host disease who have inadequate response to corticosteroids.	Not routinely available as not recommended for use in NHS Scotland	15/06/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/ruxolitinib-jakavi-nonsub-smc2498/>

Other Decision Specified

Date of ADTC 15/06/2022

Tepotinib 225mg film-coated tablets (Tepmetko®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2457	For the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations.	Not routinely available as not recommended for use in NHS Scotland	15/06/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/tepotinib-tepmetko-full-smc2457/>

Other Decision Specified

Date of ADTC 15/06/2022

Ixekizumab 80mg solution for injection in pre-filled syringe or pen (Taltz®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2440	<p>Ankylosing spondyloarthritis (radiographic axial spondyloarthritis)</p> <p>-Treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy.</p> <p>-Non-radiographic axial spondyloarthritis</p> <p>Treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).</p>	Not routinely available as not recommended for use in NHS Scotland	15/06/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/ixekizumab-taltz-full-smc2440/>

Other Decision Specified

Date of ADTC 15/06/2022

Abrocitinib 50mg, 100mg, and 200mg film-coated tablets (Cibinqo®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2431	For the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. SMC restriction: for use in patients who have not responded to, or have lost response to, at least one systemic immunosuppressant therapy, or in whom these are contraindicated or not tolerated.	Not routinely available as the ADTC is waiting for further advice from local clinical experts – decision expected by	30/09/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/abrocitinib-cibinqo-full-smc2431/>

Other Decision Specified

Date of ADTC 15/06/2022

Relugolix 40mg, estradiol 1mg, norethisterone acetate 0.5mg film-coated tablets (Ryeqo®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2442	Treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. SMC restriction: for use in patients who have failed or are unsuitable for conventional therapies (first line treatments), such as tranexamic acid, hormonal contraceptives and intrauterine delivery systems.	Not routinely available as the ADTC is waiting for further advice from local clinical experts – decision expected by	30/09/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/relugolixestradiolnorethisterone-acetate-ryeqo-full-smc2442/>

Other Decision Specified

Date of ADTC 15/06/2022

Lenvatinib 4mg and 10mg hard capsules (Kispalyx®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2476	Treatment of adults with advanced renal cell carcinoma (RCC), in combination with pembrolizumab, as first-line treatment. SMC restriction: treatment with pembrolizumab is subject to a two-year clinical stopping rule.	Not routinely available as the ADTC is waiting for further advice from local clinical experts – decision expected by	30/09/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/lenvatinib-kispalyx-abb-smc2476/>

Other Decision Specified

Date of ADTC 15/06/2022
